

Mingxiang Liao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8068448/publications.pdf>

Version: 2024-02-01

6
papers

211
citations

1683354

5
h-index

1872312

6
g-index

6
all docs

6
docs citations

6
times ranked

243
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 836-864.	2.3	141
2	Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 765-775.	1.2	26
3	Evaluation of <i>in vitro</i> absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor. <i>Xenobiotica</i> , 2020, 50, 1032-1042.	0.5	25
4	Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 259-270.	1.1	11
5	A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 887-897.	1.1	6
6	Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 711-723.	0.6	2